PMID- 37347355
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20230724
IS  - 2038-3312 (Electronic)
IS  - 2038-131X (Print)
IS  - 2038-131X (Linking)
VI  - 75
IP  - 5
DP  - 2023 Aug
TI  - Evaluation of peritoneal Carcinoembryonic Antigen as a survival prognostic factor 
      in gastric cancer patients: a single western center experience.
PG  - 1211-1217
LID - 10.1007/s13304-023-01542-3 [doi]
AB  - The aim of this study is to define the importance of peritoneal CEA (pCEA) as a 
      prognostic factor of overall survival (OS) and disease-free survival (DFS) in 
      gastric cancer (GC) patients surgically treated with a curative intent In our 
      department. A total of 64 patients affected by gastric cancer with 
      intraoperatively measurement of CEA on peritoneal lavage were enrolled in the 
      study. Patients were divided into two groups: (A) the peritoneal lavage CEA ( -) 
      with CEA < 0.5 ng/ml and (B) the peritoneal lavage CEA ( +) with CEA >/= 0.5 ng/ml. 
      Then we analyzed OS and DFS of the two groups correlating them to others 
      clinico-pathological features. Furthermore, we investigated the correlation 
      between pCEA and peritoneal cytology. We demonstrated a strong significant 
      difference in OS and in DFS in CEA ( +) patients. We emphasized that pCEA had a 
      strong survival impact, in both OS and DFS, in selected patients affected by 
      diffuse histotype GC (p = 0.0048 and p = 0.0030 respectively), stage III 
      (p = 0.015 and p = 0.021, respectively) and distal gastric cancer (p = 0.0036 and 
      p = 0.0017, respectively). There is a strong need to recognize prognostic factors 
      that can help clinicians to stratify patients at high risk to develop 
      post-surgical recurrences and moreover to recognize who could benefit from an 
      aggressive surgical treatment of cytoreductive surgery and intra-peritoneal 
      chemotherapy.pCEA is a good predictor of survival in advanced gastric cancer and 
      could discriminate which patients need a more accurate follow-up program and an 
      intensive therapeutic strategy.
CI  - (c) 2023. The Author(s).
FAU - Natalizi, Nicola
AU  - Natalizi N
AD  - General and Emergency Surgery, Santa Maria della Misericordia Hospital-University 
      of Perugia, Via dottori, 06132, Perugia, Italy.
FAU - Marino, Elisabetta
AU  - Marino E
AD  - General and Emergency Surgery, Santa Maria della Misericordia Hospital-University 
      of Perugia, Via dottori, 06132, Perugia, Italy.
FAU - Graziosi, Luigina
AU  - Graziosi L
AD  - General and Emergency Surgery, Santa Maria della Misericordia Hospital-University 
      of Perugia, Via dottori, 06132, Perugia, Italy. luiginagraziosi@yahoo.it.
FAU - Donini, Annibale
AU  - Donini A
AD  - General and Emergency Surgery, Santa Maria della Misericordia Hospital-University 
      of Perugia, Via dottori, 06132, Perugia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230622
PL  - Italy
TA  - Updates Surg
JT  - Updates in surgery
JID - 101539818
RN  - 0 (Carcinoembryonic Antigen)
SB  - IM
MH  - Humans
MH  - *Carcinoembryonic Antigen
MH  - Prognosis
MH  - *Stomach Neoplasms/pathology
MH  - Peritoneal Lavage
MH  - Peritoneum
PMC - PMC10359201
OTO - NOTNLM
OT  - Carcinoembryonic Antigen
OT  - Gastric cancer
OT  - Peritoneal washing
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/22 13:09
MHDA- 2023/07/21 06:43
PMCR- 2023/06/22
CRDT- 2023/06/22 11:10
PHST- 2022/12/28 00:00 [received]
PHST- 2023/05/15 00:00 [accepted]
PHST- 2023/07/21 06:43 [medline]
PHST- 2023/06/22 13:09 [pubmed]
PHST- 2023/06/22 11:10 [entrez]
PHST- 2023/06/22 00:00 [pmc-release]
AID - 10.1007/s13304-023-01542-3 [pii]
AID - 1542 [pii]
AID - 10.1007/s13304-023-01542-3 [doi]
PST - ppublish
SO  - Updates Surg. 2023 Aug;75(5):1211-1217. doi: 10.1007/s13304-023-01542-3. Epub 
      2023 Jun 22.